# A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.

> **NCT04027517** · PHASE3 · COMPLETED · sponsor: **JW Pharmaceutical** · enrollment: 172 (actual)

## Conditions studied

- Anemia of Chronic Kidney Disease

## Interventions

- **DRUG:** JTZ-951
- **DRUG:** Darbepoetin Alfa

## Key facts

- **NCT ID:** NCT04027517
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-15
- **Primary completion:** 2021-02-23
- **Final completion:** 2021-02-23
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2021-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04027517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04027517, "A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04027517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*